Does azacitidine alter ruxolitinib's toxicity levels?

Short answer: There is no major pharmacokinetic interaction between azacitidine and ruxolitinib, but the combination can increase toxicity because both drugs cause bone marrow suppression.

Details:
- Pharmacokinetics: Azacitidine is not a significant CYP450 substrate/inhibitor and does not meaningfully affect ruxolitinib exposure. Likewise, there’s no strong evidence that ruxolitinib alters azacitidine metabolism. So, no predictable PK interaction that would change toxicity levels via drug levels.
- Pharmacodynamics: Both drugs can cause cytopenias (anemia, thrombocytopenia, neutropenia). When used together, there is a higher risk of additive/myelosuppressive toxicity and related complications (infections, fatigue, need for transfusions).
- Clinical implications: If this combination is used (often within a trial or specific treatment plan), expect closer hematologic monitoring (e.g., CBC before each cycle or more often initially). Dose adjustments may be needed:
- If cytopenias develop, reduce or hold ruxolitinib or adjust azacitidine per protocol.
- Provide supportive care as indicated (transfusions, infection management).
- Practical note: In real-world use, this combination is usually guided by clinical trial protocols with predefined dose modification rules due to the higher risk of cytopenias.

If you have a specific indication (e.g., myelodysplastic syndrome, myelofibrosis) or a regimen in mind, I can look up or summarize the relevant study data and dosing guidelines. And as always, discuss with the treating oncologist/hematologist for personalized advice.